Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma

Table 1 Summary of the phase I clinical trials of custirsen

Clinical trial	Notes	Drugs	Patients, n	Phase
OGX-011-01[24]	Dose escalation, single-center study in patients receiving hormone therapy and custirsen prior to radical prostatectomy	Buserelin, custirsen sodium, flutamide	25	I
Hormone therapy and OGX-011 before radical prostatectomy in treating patients with prostate cancer (NCT00054106)
OGX-011-2[25]	Dose escalation, multi-center, study with custirsen in combination with docetaxel in patients with CRPC, NSCLC, breast, ovarian, bladder or renal cancer	Custirsen sodium, docetaxel	40	I
OGX-011 and docetaxel in treating patients with metastatic or locally recurrent solid tumors (NCT 00471432)
OGX-011-10	Open-label, one arm, one-sequence crossover drug-drug interaction study in advanced solid tumors subjects to evaluate the potential effect of custirsen on the pharmacokinetics of paclitaxel	Custirsen, paclitaxel and carboplatin	36	I
A clinical study in cancer patients to investigate the potential impact of custirsen on the blood levels of the chemotherapeutic drug, paclitaxel, when given together as part of a treatment regimen (NCT01497470)